SUO 2016: Novel predictive biomarkers for benefit of immune checkpoint blockade - Session Highlights

San Antonio, Texas USA ( William Kim, University of North Carolina, discussed biomarkers in the immune checkpoint blockade. The biomarkers currently explored are PDL-1 and mutational load. PDL-1 + is a biomarker of response, however, there are patients who are negative which also have response to PDL-1 inhibitors.

SUO 2016: Definite Treatment of Bladder Cancer in Octogenarians: Balancing Increased Perioperative Mortality with Superior Overall Survival - Poster Session Highlights

San Antonio, Texas USA ( Radical cystectomy (RC) is the gold standard therapy for patient with muscle invasive bladder cancer (MIBC) as is the treatment associated with the best oncological outcomes. However, RC comes with great morbidity with overall 90 day complication rate of approximately 30%. Thus, RC has been seldomly performed in elderly patients especially those in the later decades of life.

SUO 2016: Absence of Tumor on Repeat TURBT does not Predict Final Pathologic T0 Stage in Muscle Invasive Bladder Cancer Treated with Radical Cystectomy - Poster Session Highlights

San Antonio, Texas USA ( For patients with muscle invasive bladder cancer (MIBC) who undergo neoadjuvant chemotherapy (NAC) the best predictor of response and prognosis is pT0 stage in the cystectomy specimen. There has been recent evidence that cystoscopy evidence of cT0 may be a good clinical surrogate of pT0 in the cystectomy specimen. Several groups are now looking into omitting radical cystectomy for patients with good response to NAC who appear to be cT0 on cystoscopic evaluation or following a repeat TURBT.

SUO 2016: Novel Immune Approaches to Muscle Invasive Bladder Cancer - Session Highlights

San Antonio, Texas USA ( Neoadjuvant chemotherapy has been a widely accepted part of the treatment algorithm and has level 1 support (Grossman et al, NEJM 2003). There has been a steady uptake in the use of neoadjuvant chemotherapy over the years (Bergerot et al, ASCO 2016).However, up to 40% of patients are not eligible for neoadjuvant therapies due to pre-existing renal dysfunction, poor performance status, and significant hearing loss. Since the approval of Atezolizumab for the treatment of metastatic bladder cancer by the FDA there has been a push for the use of immunotherapy in the neoadjuvant setting.

SUO 2016: Novel Immune Approaches for High Risk Non-muscle Invasive Bladder Cancer - Session Highlights

San Antonio, Texas USA ( The role of immunotherapy for non-muscle invasive bladder cancer (NMIBC) is particularly apt for discussion, as it has now been 40 years since the first publication of the use of BCG for the treatment of NMIBC. What we have learned since the initial introduction of BCG is that there is a complex cancer immunity cycle that affects the response of tumor cells to immune manipulation.

SUO 2016: Targeted approaches for T1 bladder cancer - Session Highlights

San Antonio, Texas USA ( In this session, Dr. Bellmunt discussed a more targeted approach in the treatment of T1 bladder cancer. His goal was to help generate hypotheses to inform future clinical trial design focused on proper risk stratification at initial diagnosis (not only stage and grade), early identification of patients with high risk of progression, and optimization of follow-up schema.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.